Reinvigorated PD-1(+) T-cell response to anti-PD-1 therapy in peripheral blood peaks at 3rd week after the initiation of treatment.[4] Thrombosis as an irAE can be associated with the surge of reinvigorated T cells soon after pembrolizumab administration. Here, PDCD1 is linked to deep vein thrombosis.